Search Results
Dec 30, 2025, 13:02 ET Rural Development Partners Receives $90 Million NMTC Award, Boosting Economic Development for Rural America
maximize economic growth for America. Rural Development Partners Rural Development Partners is a Community Development Entity (CDE) with a national service area eligible to apply for an annual allocation of federal New Markets Tax Credits. RDP partners with businesses, non-profit
More news about: Rural Development Partners
Dec 29, 2025, 14:37 ET Florida Community Loan Fund Awarded $75 Million New Markets Tax Credit Allocation from U.S. Department of Treasury
CDFI and CDE through the U.S. Department of Treasury and as a member of the Federal Home Loan Bank of Atlanta. Learn more at
More news about: Florida Community Loan Fund (FCLF)
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
locally advanced or metastatic renal cell carcinoma who previously failed systematic treatment, has been accepted by the Center for Drug Evaluation (CDE) of NMPA.In addition, two clinical studies of sintilimab have met their primary endpoints:Phase 2 study of sintilimab
More news about: Innovent Biologics
Dec 22, 2025, 06:33 ET New Gold Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order and Competition Act Approval
the Business Corporations Act (British Columbia), whereby a wholly-owned subsidiary (the "Purchaser") of Coeur Mining, Inc. ("Coeur") (NYSE: CDE) will acquire all of the issued and outstanding common shares of New Gold (the "Transaction"). Under the terms of the Transaction, New Gold shareholders
More news about: New Gold Inc.
Dec 22, 2025, 05:07 ET AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
marks a critical milestone in our mission to advance a functional cure for chronic hepatitis B. Full enrollment was achieved within five months of China CDE approval, reflecting the strong engagement and dedication of the investigators, patients, clinical teams who partnered with us in this program. We are
More news about: AusperBio Therapeutics Inc.
Dec 17, 2025, 11:55 ET The Race for Resources: $4,300 Gold Triggers Aggressive Global Drilling Frenzy
GHVNF), Omai Gold Mines Corp. (TSXV: OMG) (OTCQB: OMGGF), Fortuna Mining Corp. (NYSE: FSM) (TSXL FVI), Coeur Mining, Inc. (NYSE: CDE), and Hecla Mining Company (NYSE: HL).
More news about: USA News Group
Dec 12, 2025, 07:00 ET Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)
animal models; and a safety profile characterized by higher maximum tolerated doses and broad safety margins. The program received IND clearance from the CDE in China in 2023."We are delighted to collaborate with TaiGen Biotech," said Feng Ren, PhD, Co-CEO and CSO of Insilico Medicine. "Powered
More news about: Insilico Medicine
Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
combination therapy for first-line TNBC was previously included in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). Currently, the multicenter, randomized, double-blind Phase III clinical trial (HARMONi-BC1/AK112-308)
More news about: Akeso, Inc.
Dec 09, 2025, 05:00 ET Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
months.Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published
More news about: Dizal Pharmaceutical
Dec 08, 2025, 21:02 ET Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
(sNDA) for ivonescimab in combination with chemotherapy as first-line treatment for sq-NSCLC was accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). Akeso's partner, Summit Therapeutics, is currently carrying out a global multicenter Phase
More news about: Akeso, Inc.
Dec 04, 2025, 10:00 ET Europe's Car Design Event 2026 Moves to March
private setting to present their latest creations, share ideas and discuss the latest auto-industry developments," said CDE cofounder Jens Meiners. "Lively debate lies at the heart of CDE with topics including the future of mobility, vehicle-design trends and the use of AI in automotive design."Meiners
More news about: Car Design Event
Dec 04, 2025, 07:08 ET Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development
Previously, HMI-115 had been included in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), intended for the treatment of moderate to severe pain associated with endometriosis. This
More news about: Hope Medicine
Dec 03, 2025, 20:57 ET INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration ("NMPA") of the PRC, with the proposed indication for the treatment of adults with unresectable advanced
More news about: TransThera Sciences (Nanjing) Inc.
Dec 02, 2025, 08:51 ET FWD STRATEGIES Launches to Help Leaders and Organizations Move Forward With Clarity and Purpose
FWD STRATEGIES is led by Bob Osmond, ACC, CPC, CDE®, a professional coach and communications expert with more than 30 years of experience working with B2B, consumer, technology, and professional services
More news about: FWD STRATEGIES, LLC
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and was included in the priority review and approval process.As of today, the Company
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 25, 2025, 04:00 ET Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This application of mazdutide 9 mg aims to address a pressing unmet clinical need in
More news about: Innovent Biologics
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
meaningful improvement in PFS. Based on the results from the interim analysis, the Company plans to communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China regarding the submission of a supplemental new drug application (sNDA) of sac-TMT.Sac-TMT
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 21, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-KVUE, KMB, SM, and CDE
CDE) related to its merger with New Gold, Inc. Upon completion of the proposed transaction, Coeur shareholders will own approximately 62% of the combined
More news about: Monteverde & Associates PC
Nov 19, 2025, 19:00 ET Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
secondary endpoints. Innovent plans to submit the new drug application (NDA) of mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in the near term. GLORY-2 (NCT06164873) is a Phase 3 clinical study
More news about: Innovent Biologics
Nov 19, 2025, 10:25 ET Precisely kündigt Gio™ AI Assistant und Data Catalog Agent in der Data Integrity Suite an
Automatisierung: Der Data Catalog Agent automatisiert laufende Datenkatalogisierungsaufgaben wie die Dokumentation und Klassifizierung von PII und CDE und sorgt so dafür, dass Ihre Daten konform und vernetzt bleiben. Auswahl und Kontrolle: Kunden
More news about: Precisely
Nov 19, 2025, 10:24 ET Precisely annonce Gio™ AI Assistant et Data Catalog Agent dans la Data Integrity Suite
L'agent Data Catalog automatise l'identification et le balisage des informations personnellement identifiables (PII) et des éléments de données critiques (CDE), ce qui permet une gouvernance plus rapide et plus cohérente. D'autres agents suivront dans les semaines à venir, étendant l'automatisation à d'autres
More news about: Precisely
Nov 19, 2025, 09:00 ET Precisely Announces Gio™ AI Assistant and Data Catalog Agent in the Data Integrity Suite
Scalable automation: The Data Catalog Agent automates ongoing data cataloging tasks such as documenting and classifying PII and CDE, to help keep your data compliant and connected. Choice and control: Customers define the guardrails,
More news about: Precisely
Nov 19, 2025, 09:00 ET Precisely Announces Gio™ AI Assistant and Data Catalog Agent in the Data Integrity Suite
Scalable automation: The Data Catalog Agent automates ongoing data cataloging tasks such as documenting and classifying PII and CDE, to help keep your data compliant and connected. Choice and control: Customers define the guardrails,
More news about: Precisely
Nov 13, 2025, 10:16 ET Commercial Display Market to Reach $92.3 billion, Globally, by 2034 at 6.2% CAGR: Allied Market Research
further drive the market. For instance, in June 2025, ViewSonic launched its next-generation large-format commercial displays, including the 92-inch CDE92UW, designed for Microsoft Teams Rooms and digital signage applications. Featuring a 5K resolution and 21:9 ultra-wide aspect ratio, the display offers
More news about: Allied Market Research
Nov 11, 2025, 13:53 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
Developmental and Epileptic Encephalopathies (DEEs), has been granted Breakthrough Therapy Designation (BTD) by China's Center for Drug Evaluation (CDE). The BTD procedure is designed to accelerate the development and review of innovative medicines for serious or life-threatening diseases with no adequate
More news about: H. Lundbeck A/S